Summary:
- The article discusses the challenges faced by the U.S. Food and Drug Administration (FDA) in ensuring the quality and safety of generic drugs.
- It highlights concerns about the FDA's ability to effectively monitor the manufacturing of generic drugs, especially those produced in foreign countries.
- The article suggests that the FDA's limited resources and the increasing complexity of the global pharmaceutical supply chain have made it difficult for the agency to thoroughly inspect and test all generic drug products.